Literature DB >> 22368724

Dysmetabolic Signals in "Metabolically Healthy" Obesity.

Peter Manu1, Constantin Ionescu-Tirgoviste, James Tsang, Barbara A Napolitano, Martin L Lesser, Christoph U Correll.   

Abstract

BACKGROUND: Obesity is associated with decreased insulin sensitivity, atherogenic dyslipidemia and hypertension, but clinical studies have also identified a "metabolically healthy" obese phenotype.
OBJECTIVE: To compare the characteristics of so-called "metabolically healthy" obese (MHO), normal weight subjects (MHNW) and obese with insulin resistance in a nationally representative sample in the United States. DESIGN, SETTING AND PARTICIPANTS: Insulin resistance was defined by a homeostatic model assessment (HOMA) value in the upper tertile for the entire NHANES cohort. "Metabolic health" was defined as the absence of diabetes, insulin resistance, metabolic syndrome, and lipid-lowering therapy. The study evaluated the 314 MHO, 1173 MHNW and 843 insulin-resistant obese from among the 6485 non-diabetic, nno-pregnant adults aged 20-79 years, who participated to the United States National Health and Nutrition Examination Survey, 1999-2004. MAIN OUTCOME MEASURES: Demographic, metabolic, nutrition and physical activity features.
RESULTS: MHO and MHNW groups were similar regarding age, and fasting glucose and triglyceride levels. MHO had higher insulin (P<0.0001), insulin resistance as measured with the homeostatic model (p<0.0001), non-HDL cholesterol (P=0.002 in females and P=0.049 in males) and C-reactive protein levels (P<0.0001 in females and P=0.038 in males), and lower high-density lipoprotein cholesterol (HDL) levels (P<0.002). In addition, MHO females had higher low-density lipoprotein (LDL) cholesterol levels (P=0.012) and systolic blood pressure (P=0.02), and lower intake of dietary fiber (P=0.0009) and levels of physical activity (p=0.002). Triglycerides levels were normal in the MHO group.
CONCLUSIONS: "Metabolically healthy" obese people have multiple dysmetabolic changes that may signal increased risk for coronary artery disease.

Entities:  

Year:  2012        PMID: 22368724      PMCID: PMC3285381          DOI: 10.1016/j.orcp.2011.04.003

Source DB:  PubMed          Journal:  Obes Res Clin Pract        ISSN: 1871-403X            Impact factor:   2.288


  45 in total

1.  Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.

Authors:  James B Meigs; Martin K Rutter; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; Peter W F Wilson
Journal:  Diabetes Care       Date:  2007-01-26       Impact factor: 19.112

2.  Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease.

Authors:  Martin K Rutter; Peter W F Wilson; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; James B Meigs
Journal:  Circulation       Date:  2008-02-04       Impact factor: 29.690

3.  Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report.

Authors:  Petra Schnell-Inderst; Ruth Schwarzer; Alexander Göhler; Norma Grandi; Kristin Grabein; Björn Stollenwerk; Jennifer Manne; Volker Klauss; Uwe Siebert; Jürgen Wasem
Journal:  Int J Technol Assess Health Care       Date:  2010-01       Impact factor: 2.188

4.  Trends in hyperinsulinemia among nondiabetic adults in the U.S.

Authors:  Chaoyang Li; Earl S Ford; Lisa C McGuire; Ali H Mokdad; Randie R Little; Gerald M Reaven
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

Review 5.  Are there persons who are obese, but metabolically healthy?

Authors:  E A Sims
Journal:  Metabolism       Date:  2001-12       Impact factor: 8.694

6.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

7.  [Sensitivity and specificity of metabolic syndrome criteria for insulin resistance diagnosis in Spanish population].

Authors:  Erardo Meriño-Ibarra; Ana Cenarro; Paula Martín; Angel Luis García-Otín; Jesús Goicoechea; Ana Guallar; Luisa Calvo; Fernando Civeira
Journal:  Med Clin (Barc)       Date:  2007-02-10       Impact factor: 1.725

8.  Inaccuracies in food and physical activity diaries of obese subjects: complementary evidence from doubly labeled water and co-twin assessments.

Authors:  K H Pietiläinen; M Korkeila; L H Bogl; K R Westerterp; H Yki-Järvinen; J Kaprio; A Rissanen
Journal:  Int J Obes (Lond)       Date:  2009-12-15       Impact factor: 5.095

9.  The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004).

Authors:  Rachel P Wildman; Paul Muntner; Kristi Reynolds; Aileen P McGinn; Swapnil Rajpathak; Judith Wylie-Rosett; MaryFran R Sowers
Journal:  Arch Intern Med       Date:  2008-08-11

10.  Indexes of insulin resistance and secretion in obese children and adolescents: a validation study.

Authors:  Louise S Conwell; Stewart G Trost; Wendy J Brown; Jennifer A Batch
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

View more
  12 in total

1.  Metabolically Healthy Obesity Is Not Associated with Food Intake in White or Black Men.

Authors:  Ruth W Kimokoti; Suzanne E Judd; James M Shikany; P K Newby
Journal:  J Nutr       Date:  2015-09-30       Impact factor: 4.798

2.  Food intake does not differ between obese women who are metabolically healthy or abnormal.

Authors:  Ruth W Kimokoti; Suzanne E Judd; James M Shikany; P K Newby
Journal:  J Nutr       Date:  2014-10-08       Impact factor: 4.798

Review 3.  Metabolically healthy obesity--does it exist?

Authors:  Patchaya Boonchaya-anant; Caroline M Apovian
Journal:  Curr Atheroscler Rep       Date:  2014-10       Impact factor: 5.113

Review 4.  Metabolically healthy obesity: definitions, determinants and clinical implications.

Authors:  Catherine M Phillips
Journal:  Rev Endocr Metab Disord       Date:  2013-09       Impact factor: 6.514

5.  Utility of obesity indicators for metabolically healthy obesity: an observational study using the Korean National Health and Nutrition Examination Survey (2009-2010).

Authors:  Min-Kyu Choi; Young-Ah Han; Yong Kyun Roh
Journal:  BMC Public Health       Date:  2014-11-14       Impact factor: 3.295

6.  Factors associated with metabolically healthy status in obesity, overweight, and normal weight at baseline of ELSA-Brasil.

Authors:  Maria de Fátima Haueisen Sander Diniz; Alline Maria Rezende Beleigoli; Antônio Luiz P Ribeiro; Pedro Guatimosim Vidigal; Isabela M Bensenor; Paulo A Lotufo; Bruce B Duncan; Maria Inês Schmidt; Sandhi Maria Barreto
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Quercetin Preserves β -Cell Mass and Function in Fructose-Induced Hyperinsulinemia through Modulating Pancreatic Akt/FoxO1 Activation.

Authors:  Jian-Mei Li; Wei Wang; Chen-Yu Fan; Ming-Xing Wang; Xian Zhang; Qing-Hua Hu; Ling-Dong Kong
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-27       Impact factor: 2.629

8.  All-cause mortality risk of metabolically healthy obese individuals in NHANES III.

Authors:  C M Durward; T J Hartman; S M Nickols-Richardson
Journal:  J Obes       Date:  2012-12-05

9.  Defining metabolically healthy obesity: role of dietary and lifestyle factors.

Authors:  Catherine M Phillips; Christina Dillon; Janas M Harrington; Vera J C McCarthy; Patricia M Kearney; Anthony P Fitzgerald; Ivan J Perry
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  Metabolism rather than obesity is associated with ischemic stroke: a cross-sectional study in rural Northeastern China.

Authors:  Zhao Li; Xiaofan Guo; Yamin Liu; Naijin Zhang; Ye Chang; Yintao Chen; Yingxian Sun; Maria Roselle Abraham
Journal:  Springerplus       Date:  2016-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.